Skip to main content

Advancing Alzheimer’s and related dementias research: FY 2022 NIH bypass budget and progress report

Dr. Richard Hodes
Richard J. HODES,
Office of the Director (OD)

Our recent blog post about NIA’s Strategic Directions: Priorities for continued progress included mention of the annual NIH Professional Judgment Budget for Alzheimer’s Disease and Related Dementias, submitted in response to legislative requirement and as one way NIA communicates our research priorities. Beginning in fiscal year (FY) 2015, each July NIH has submitted this “bypass budget” for Alzheimer’s and related dementias research to Congress. On July 20, I presented this information for FY 2022 during a virtual meeting with the HHS Secretary’s Advisory Council on Alzheimer’s Research, Care, and Services, and it was published simultaneously on our public website.

FY 2021 bypass budget report cover To develop the annual bypass budget estimate, we worked over many months to analyze research investments and progress against our research implementation milestones for Alzheimer’s and related dementias. The FY 2022 NIH bypass budget asks for $289 million in additional resources for new research, with the overall resources needed totaling $3.1 billion.

This year, the global coronavirus pandemic has cast a spotlight on the special vulnerability of people with dementia, particularly those from disadvantaged minority communities, and we are more driven than ever to develop solutions for them, their families, and their communities.

Apply for funding opportunities

What does this mean for scientists? As the title “Expanding collaborative, cross-disciplinary research for dementia prevention, treatment, and care” implies, it calls for researchers to be part of that expansion to help us meet the National Alzheimer’s Project Act goal of preventing or effectively treating for Alzheimer’s by 2025. Our success depends on you, so be sure to apply for NIA grants!

To better understand our research priorities, you can peruse our current NIA funding opportunity announcements in Alzheimer's and related dementias research. We invite you to contact our program officials for more information, as well as to sign up for our email listserv to learn about new funding opportunities as they are published.

Tell us about your research progress

The progress report portion of the annual budget highlights some of the major Alzheimer’s and related dementias research papers from NIH-supported studies published in the past year. We describe how NIH investments have led to advances in the development of both pharmaceutical and nonpharmaceutical interventions, comprehensive models of dementia care, and new biomarker assays and imaging agents.

When your manuscript about significant findings for dementia-related research is accepted, please share it with your NIA program official and the NIA Press Team. We feature selected papers as snapshots for the progress report, as well as stories and news releases for the NIA website. Help us demonstrate the value of investments in Alzheimer’s and related dementias research by keeping us informed of your accomplishments.

Share your ideas!

Please use the comment field below to share your thoughts on the latest budget report. We have already begun to work on the FY 2023 progress report about important research findings and look forward to your input!


Submitted by Anonymous on July 22, 2020

Funding opportunities are urgently needed in order to promote health disparity related ADRD research.

Submitted by Xianghong Arakaki on July 24, 2020

We are thankful for the NIH support of our study: “Cognitive challenge to reveal pre-symptomatic Alzheimer's disease (AD)”, award number R56AG063857.

Changes in biomarkers (amyloid/tau) and synaptic functions precede cognitive decline in Alzheimer’s disease (AD) by decades. We are interested in studying the functional electroencephalogram (EEG) to reveal synaptic changes of interacting conscious, subliminal, and autonomic (CSA) system in pre-symptomatic AD, to improve our understanding of pre-symptomatic AD. The CSA biomarkers are minimally invasive, with screen potential for further staging purposes, and to plan and test therapy.

Our study receives strong support from multi-disciplinary collaborations (Dr. Shimojo in Caltech and Dr. Kleinman in UCI) that bridge the gap between neuroscience, psychology, and cardiovascular biology.

Our supported work has led this year to two published abstracts at Experimental Biology 2020 and four accepted abstracts/presentation in the coming AAIC 2020. We fully appreciate and support the FY 2022 NIH bypass budget.

Xianghong Arakaki, MD, PhD
Principal Investigator, Neurosciences
Huntington Medical Research Institutes (HMRI)

Michael G. Harrington, MB, ChB, FRCP
Scientific Director, Neurosciences

Add new comment

Your e-mail address will not be posted.

Plain text

  • Allowed HTML tags: <p> <br>
  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.